Key facts
- Polimerbio’s last known valuation is $6.4M (Dec 2025).
- It has raised $3.5M; the latest was Later Stage VC ($1.1M) in Dec 2025.
- Notable investors include Clave (Pamplona), CDTI Innvierte, BIC Araba, Caja de Ahorros y Monte de Piedad de Gipuzkoa y San Sebastián, Ekin + Program — 10 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 10 names
- ·Watchlist + deal alerts for Polimerbio
- ·The full record, as it builds
Funding rounds
No funding rounds for Polimerbio are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Polimerbio
Developer of polymer-based medical devices designed to replace non-biodegradable devices and improve soft tissue regeneration. The company's devices are created by using new materials for biomedical devices and tissue engineering, enabling medical professionals to reduce surgical interventions and hospital costs and improve patients' quality of life.
- Sector
- Healthcare
- HQ
- Donostia-San Sebastian, Spain
- Founded
- 2017
- Employees
- 13
- Website
- polimerbio.com/
- Ownership
- Privately Held (backing)
Polimerbio doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Polimerbio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Polimerbio in its N-PORT filings yet. We sweep new filings monthly.